Dr. Thomas Lundbäck is currently a Director within the Discovery Sciences organisation at AstraZeneca R&D. Thomas is a drug discovery professional with more than two decades of experience in the field of assay development, compound profiling, and detailed mechanism of action studies in a broad range of different biochemical and cellular assay formats. Having worked between pharmaceutical industry and academia, Thomas is currently responsible for a team of scientists in the Mechanistic and Structural Biology department, the mission of which is to support the therapeutic area organizations with SAR profiling, early DMPK and safety profiling and structure and biophysics. Thomas is also chairman of the steering group for Chemical Biology Consortium Sweden, where he worked between 2010-2016. It was in this setting he encountered the cellular thermal shift assay (CETSA) and played a key role in the addition of high throughput screening capacity to this technology.